Ozon Pharmaceuticals under IFRS for 3 months of 2025

Ozon Pharmaceuticals ' IFRS net profit for 3 months of 2025 was ₽0.993 billion, an increase of 28% compared to ₽0.776 billion in the previous year. Revenue increased by 45.2% to ₽6.855 billion from ₽4.722 billion a year earlier.